Published Technical Disclosure Archive

Synergistic Cancer Treatment System with AI, IoT, Blockchain, and Nanoparticle Delivery

Publication ID: 24-11857601_0003_PTD
Published: October 28, 2025
Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “Synergistic Cancer Treatment System with AI, IoT, Blockchain, and Nanoparticle Delivery,” Published Technical Disclosure No. 24-11857601_0003_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857601_0003_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,601.

Summary of the Inventive Concept

A novel cancer treatment system integrating a fusion protein dimer with IL-2 and CD80 proteins, an anticancer agent, and advanced technologies like AI, IoT, blockchain, and nanoparticle delivery to enhance treatment efficacy, patient monitoring, and data management.

Background and Problem Solved

The original patent disclosed a pharmaceutical composition for cancer treatment comprising a fusion protein dimer and an anticancer agent. However, this invention has limitations in terms of treatment monitoring, data management, and personalized treatment strategies. The new inventive concept addresses these limitations by integrating distinct technologies to create a more powerful and effective system.

Detailed Description of the Inventive Concept

The system comprises a fusion protein dimer including IL-2 protein and CD80 protein, an anticancer agent, and a blockchain-based data storage module for tracking patient treatment history and outcomes. Additionally, the system incorporates an AI-powered algorithm for predicting treatment efficacy based on patient-specific biomarkers and a nanoparticle-based delivery system for targeted and controlled release of the fusion protein and anticancer agent. The system may also include an IoT-based wearable device for monitoring patient vital signs and adjusting treatment dosages in real-time.

Novelty and Inventive Step

The new claims introduce novel and non-obvious synergies between the fusion protein dimer, anticancer agent, and advanced technologies like AI, IoT, blockchain, and nanoparticle delivery. The inventive step lies in the integration of these distinct technologies to create a more effective and personalized cancer treatment system.

Alternative Embodiments and Variations

Alternative embodiments may include different AI algorithms, IoT devices, or nanoparticle delivery systems. Variations may also include integrating other advanced technologies, such as gene editing or immunotherapy, to further enhance treatment outcomes.

Potential Commercial Applications and Market

The synergistic cancer treatment system has significant commercial potential in the pharmaceutical and healthcare industries, particularly in the areas of personalized medicine and cancer treatment. The system's ability to enhance treatment efficacy, monitor patient outcomes, and manage data securely makes it an attractive solution for healthcare providers and patients.

CPC Classifications

SectionClassGroup
A A61 A61K38/2013
A A61 A61K31/337
A A61 A61K31/444
A A61 A61K31/4439
A A61 A61K31/47
A A61 A61K31/4709
A A61 A61K31/502
A A61 A61K31/506
A A61 A61K31/5025
A A61 A61K31/519
A A61 A61K31/708
A A61 A61K33/243
A A61 A61K38/1774
A A61 A61K39/3955
A A61 A61K45/06
A A61 A61P35/00

Field of Art

Pharmaceutical biotechnology, specifically cancer treatment technologies involving fusion proteins, targeted drug delivery, and personalized medicine approaches

Person of Ordinary Skill (PHOSITA) Profile

A biotechnology researcher with advanced degrees in molecular biology or pharmaceutical sciences, experienced in protein engineering, cancer therapeutics, and emerging medical technologies with knowledge of interdisciplinary approaches to drug development

Obviousness Rationale

A PHOSITA would recognize that integrating advanced technologies like AI, blockchain, and nanoparticle delivery with existing fusion protein cancer treatments represents a predictable extension of known personalized medicine approaches. The core fusion protein technology from the source patent provides a clear foundation for exploring enhanced delivery and monitoring methods. The proposed variations represent logical combinations of known technologies to improve cancer treatment efficacy and patient outcomes.

Obvious Combinations & Variations

Source Patent Element
Fusion protein dimer with CD80 fragment and IL-2 variant for cancer treatment
PTD Variation
Nanoparticle-based targeted delivery system for the fusion protein and anticancer agent
Obviousness Reasoning
Nanoparticle drug delivery is a well-established technique in pharmaceutical sciences for improving drug targeting and reducing systemic toxicity, making this combination a predictable optimization of the source patent's core technology
Source Patent Element
Pharmaceutical composition with multiple anticancer agents
PTD Variation
AI-powered algorithm for predicting treatment efficacy based on patient biomarkers
Obviousness Reasoning
Machine learning approaches for personalized medicine are a known technique for optimizing drug selection and treatment strategies, representing a natural extension of precision medicine principles
Source Patent Element
Cancer treatment pharmaceutical composition
PTD Variation
Blockchain-based data storage module for tracking patient treatment history
Obviousness Reasoning
Blockchain technology for medical record management is an emerging standard approach for secure, transparent patient data tracking, representing an obvious technological integration
Source Patent Element
Pharmaceutical composition with multiple anticancer agents
PTD Variation
IoT-based wearable device for real-time patient monitoring and treatment adjustment
Obviousness Reasoning
Remote patient monitoring and adaptive treatment protocols are predictable applications of existing medical technology, particularly in personalized cancer treatment approaches
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857601 and the demonstrated interoperability of fusion protein cancer treatments with emerging technologies, a person of ordinary skill in the art would find the proposed variations obvious and lacking inventive step. The combination of known pharmaceutical composition techniques with AI, blockchain, IoT, and nanoparticle delivery represents a predictable application of existing technological approaches to cancer treatment.

Original Patent Information

Patent NumberUS 11,857,601
TitlePharmaceutical composition for cancer treatment comprising fusion protein including IL-2 protein and CD80 protein and anticancer drug
Assignee(s)GI Innovation, Inc.